Center for Personalized Medicine Team
Carl Morrison, MD, DVM
Executive Director, Center for Personalized Medicine
Dr. Carl D. Morrison joined the faculty of Roswell Park Cancer Institute in January 2007, and is currently Executive Director of the Center for Personalized Medicine, Director of the Pathology Resource Network, Director Molecular Pathology, Associate Professor of Pathology, and program member in Cancer Genetics. Prior to coming to RPCI, Dr, Morrison spent five years at faculty at The Ohio State University Medical Center after completing his residency there in Anatomic Pathology. Dr. Morrison is a board-certified pathologist with a Certificate of Qualification in Oncology in NYS who has an interest in both clinical and research areas.
As Executive Director of the Center for Personalized Medicine, Dr. Morrison provides vision and integration with other resources at RPCI. Dr. Morrison continues to lead the Pathology Resource Network (PRN) at RPCI. The overall goal of the PRN is to facilitate access to human biospecimens for IRB-approved investigators with an emphasis on translational efforts. The services offered are quite diverse and serve a unique link between the research and clinical arena. Dr. Morrison started and previously directed the Clinical Data Network (CDN) at RPCI. The CDN is the organization of clinical data for research purposes utilizing a federated database approach. The primary goal of the CDN is the promotion of translational research at RPCI in a non-human subject research setting.
Director, Genomics Technology Laboratory
Jeffrey Conroy leads the research and clinical laboratory development team in the Center for Personalized Medicine and Molecular Pathology. He oversees and directs the technical implementation of advanced diagnostic tests (ADT) from target design through validation as a clinical assay. He built a state of the art CLIA certified next-generation sequencing (NGS) laboratory that has received NYS CLEP approval for OmniSeq Target, a compendium ADT for cancer. Prior to joining Roswell Park Cancer Institute in 1996, Jeffrey was Supervisor of the Molecular Cytogenetics Laboratory at University Hospitals of Cleveland where he developed and implemented some of the earliest molecular diagnostic laboratory developed tests. At RPCI, he was responsible for the day-to-day operations of several large NIH human and mouse genome mapping projects and maintains active participation with industrial partners for new technologies and chemistries. Jeffrey also serves as Co-Director of the RPCI Genomics Shared Resource and has overseen its expansion to offer over 50 genomics-based services, and a user base of over 200 investigators per year.
Antonios Papanicolau-Sengos, MD, MS
John Krolewski, MD, PhD
Kiersten Marie Miles, PhD
Maochun Qin, MD, MS
Eduardo Cortes Gomez
Mitsuko Korobkin, PhD
Lu Liu, PhD